Back to top
more

Paratek Pharmaceuticals, Inc. (PRTK)

(Delayed Data from NSDQ)

$5.36 USD

5.36
183,822

+0.04 (0.75%)

Updated May 3, 2019 04:00 PM ET

After-Market: $5.35 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 19.35% and 15.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

argenex SE (ARGX) Surges 27.8%: Is This an Indication of Further Gains?

argenex SE (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 7.89% and 1.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Surpass Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 3.39% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Reports Q4 Loss, Tops Revenue Estimates

Agenus (AGEN) delivered earnings and revenue surprises of -9.09% and 59.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Lags Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -40.74% and 13.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 5.71% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Codiak BioSciences, Inc. (CDAK) Reports Q4 Loss, Tops Revenue Estimates

Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 27.18% and 69.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 22.92% and 6.41%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Paratek Pharmaceuticals (PRTK) Q3 Earnings Expected to Decline

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paratek's (PRTK) Nuzyra Gets FDA's Orphan Drug Tag for NTM

The FDA bestows an Orphan Drug designation to Paratek's (PRTK) marketed drug Nuzyra for the treatment of infections caused by Nontuberculous Mycobacteria.

Paratek Pharmaceuticals (PRTK) Q2 Earnings and Revenues Miss Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -31.03% and -3.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Earnings Expected to Grow: What to Know Ahead of Q2 Release

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Misses Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -77.27% and -49.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?

Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q3 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 24.59% and 14.88%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Lags Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of -278.57% and -72.84%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Paratek Pharmaceuticals (PRTK) Report Negative Q2 Earnings? What You Should Know

Paratek (PRTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Paratek Pharmaceuticals (PRTK) Reports Q1 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 20.48% and 2.15%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Paratek Pharmaceuticals Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates

Paratek (PRTK) delivered earnings and revenue surprises of 21.36% and 87.59%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?